Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01821690
Other study ID # 1210009885
Secondary ID CFDA #: 84.133A-
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2013
Est. completion date December 2024

Study information

Verified date February 2023
Source Indiana University
Contact Rebecca Runkel, MHA
Phone (317) 329-2217
Email becky.runkel@rhin.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to improve behavior control displayed by persons with traumatic brain injury by assessing effectiveness of treatments for post-TBI irritability and aggression.


Description:

PURPOSE OF PROJECT: To study the effect expressed by persons with TBI through assessment of buspirone effectiveness for post-traumatic irritability and aggression and development of an irritability/aggression impact measure. SUMMARY OF PROJECT: It is anticipated that 74 subjects with 74 corresponding subject observers will be recruited for the treatment study. Subjects will be recruited from community and self-referrals. Interested potential participants will be scheduled for an in-person screening visit. Subjects who consent and qualify will be randomized in a 1:1 ratio, buspirone or placebo. Stratification to randomization group will occur based on the presence of major or minor depression (defined by PHQ-9 total score >5). Randomized subjects will receive active treatment or placebo. There will be 4 clinic visits. Visits will occur at baseline, for consenting and screening, day 35, day 63 and day 91. At all 4 clinic visits, both the subject and the observer will be given questionnaires regarding the subject's behavior and mood. Day 91 ends the period of the randomized clinical trial phase of the study and the subjects will begin the 1 month continuation phase of the study in which all participants receive active buspirone. The following questionnaires will be used as measures of irritability and aggression for the subject and the observer: Neuropsychiatric Inventory (NPI & NPI-Distress), Aggression & Irritability Impact Measure (AIIM) and Global Impression of Change. The following questionnaires will be dispensed to the subject only: TBI-Quality of Life-Anger, Personal Health Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7), PTSD Checklist Civilian (PCL-C), and Glasgow Outcome Scale Extended (GOS-E) The Investigator will complete the Clinical Global Impression of change at Visits 1, 2, 3, and 4. History and Physical Exam, creatinine level (kidney function) and liver function tests will be obtained for eligibility. Serum pregnancy tests will be drawn at screening for females of childbearing potential.


Recruitment information / eligibility

Status Recruiting
Enrollment 74
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Closed head injury (impaired brain function resulting from externally inflicted trauma without penetrating injury as defined below) at least 6 months prior to enrollment - Irritability that is either new or worse than level of irritability before the traumatic brain injury, by report of observer or person with TBI - Age at time of enrollment: 18 to 70 years - Voluntary informed consent of patient and observer - Subject and observer willing to comply with the protocol - Observer-rated NPI Irritability Domain score 6 or greater to include only moderate-severe irritability - Medically and neurologically stable during the month prior to enrollment. - If taking antidepressant, anxiolytic, hypnotic, or stimulant medications, no change anticipated in these medications during the month prior to enrollment - No change in therapies or medications planned during the 91-day participation - No surgeries planned during the 91-day participation - Vision, hearing, speech, motor function, and comprehension sufficient for compliance with all testing procedures and assessments - Observer (e.g.: family member, close friend, employer) with whom subject interacts sufficiently to observe occurrences of irritability. The observer interacts with the participant for a period long enough and of a nature to be able to judge the participant's irritability. The interactions would need to be adequate to judge observer distress over the irritability, severity of irritability and frequency of irritability on the following scale: < once weekly; once per week; several times per week, but not every day; essentially continuous. Exclusion Criteria: - Potential subject without a reliable observer - Penetrating head injury as defined by head injury due to gunshot, projectile or foreign object - Injury < 6 months prior to enrollment - Ingestion of buspirone during the month prior to enrollment - Inability to interact sufficiently for communication with caregiver - History of schizophrenia or psychosis - Diagnosis of progressive or additional neurologic disease - Clinical signs of active infection

Study Design


Intervention

Drug:
Buspirone
Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
Placebo
The placebo tablets taste and look identical to buspirone.

Locations

Country Name City State
United States Indiana University and Rehabilitation Hospital of Indiana Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuropsychiatric Inventory-Irritability Domain A self-report measure of irritability Day 91
Secondary Neuropsychiatric Inventory-Aggression Domain A self-report measure of aggression Day 91
Secondary Neuropsychiatric Inventory-Distress Irritability Domain A self-report measure of the distress caused by irritability Day 91
Secondary Neuropsychiatric Inventory-Distress Aggression Domain A self-report measure of the distress caused by aggression Day 91
Secondary St. Andrews-Swansea Neurobehavioural Outcome Scale A self-report measure of overall neurobehavioral function Day 91
Secondary Personal Health Questionnaire A measure of depression that maps on to DSM criteria for depression Day 91
Secondary Traumatic Brain Injury-Quality of Life Anger A self-report measure of overall impact of anger on quality of life Day 91
Secondary Global Impressions of Change A self-report measure of overall change Day 91
Secondary Clinical Global Impressions Clinician rating of overall change Day 91
Secondary Aggression and Irritability Impact Measure A self-report measure of overall impact of irritability on life participation 91 Day
Secondary Generalized Anxiety Disorder A self-report measure of anxiety 91 day
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1